In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

12月25日，翰宇药业发布企业公告消息称，其近日收到美国食品药品监督管理局的通知，由翰宇药业及 Hikma Pharmaceuticals USA, Inc.联合向 FDA ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

THURSDAY, Dec. 26, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first generic referencing ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...